Get the Stockscreener App
1.54
9.22%
0.13
After Hours:
1.51
-0.03
-1.95%
Fibrobiologics Inc stock is traded at $1.54, with a volume of 320.03K.
It is up +9.22% in the last 24 hours and down -75.35% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$1.41
Open:
$1.4
24h Volume:
320.03K
Relative Volume:
1.12
Market Cap:
$6.99M
Revenue:
-
Net Income/Loss:
$-18.65M
P/E Ratio:
-0.2482
EPS:
-6.205
Net Cash Flow:
$-16.66M
1W Performance:
+10.00%
1M Performance:
-75.35%
6M Performance:
-82.89%
1Y Performance:
-91.95%
1-Day Range:
$1.33
$1.605
1-Week Range:
$1.275
$1.605
52-Week Range:
$1.03
$30.60
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
1.54 | 6.40M | 0 | -18.65M | -16.66M | -6.205 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Market Outlook: Does FibroBiologics Inc have a competitive edge2026 Rallies & Risk Controlled Daily Plans - baoquankhu1.vn
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity - Bitget
FibroBiologics presents preclinical data on thymic organoids By Investing.com - Investing.com India
FibroBiologics presents preclinical data on thymic organoids - Investing.com
Injectable thymus organoids restored diverse T cells in mouse studies - Stock Titan
FibroBiologics ends Webster sublease early, updates principal office address - Investing.com UK
FibroBiologics, Inc. Files Form 8-K Current Report with SEC Detailing Company Information and Nasdaq Listing - Minichart
FibroBiologics, Inc. Files 8-K/A Amendment to Update Executive Office Address and Correct Item Disclosure – April 2026 7817 - Minichart
Fibrobiologics IncEnters Lease Termination Agreement With United Fire & Casualty On April 3, 2026SEC Filing - TradingView — Track All Markets
FibroBiologics ends Webster sublease early, updates principal office address By Investing.com - Investing.com South Africa
FibroBiologics (NASDAQ: FBLG) exits Webster lease early, eyeing $0.8M savings - Stock Titan
FibroBiologics Ends Texas Sublease, Consolidates Houston Operations - TipRanks
[SCHEDULE 13G] FibroBiologics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
FibroBiologics (NASDAQ: FBLG) ends sublease to save $0.8M rent - Stock Titan
Analyst Downgrade: Is FibroBiologics Inc subject to activist investor interest2026 Opening Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Aug Patterns: Is FibroBiologics Inc subject to activist investor interest2026 Levels & Fast Moving Trade Plans - baoquankhu1.vn
Price to sales ratio of FibroBiologics, Inc. – FWB:SG00 - TradingView — Track All Markets
Price to sales ratio of FibroBiologics, Inc. – LSX:A426UV - TradingView
FibroBiologics, Inc. Financial Statements – LSX:A426UV - TradingView — Track All Markets
Aug Ideas: Is FibroBiologics Inc benefiting from interest rate changes2026 Stock Rankings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Market Review: Is FibroBiologics Inc benefiting from interest rate changes2026 Snapshot & Low Drawdown Trading Techniques - baoquankhu1.vn
FibroBiologics, Inc. Announces Reverse Stock Split and Certificate Amendment – SEC Form 8-K Filing Summary - Minichart
FibroBiologics Implements One-for-Twenty Reverse Stock Split - TipRanks
FibroBiologics (NASDAQ: FBLG) completes 1:20 reverse stock split - Stock Titan
FibroBiologics closes $3M public offering with warrants By Investing.com - Investing.com Canada
FibroBiologics Announces Closing of $3 Million Public Offering - Sahm
Fibrobiologics announces closing of $3 million public offering - marketscreener.com
Fibrobiologics Announces Closing Of $3 Million Public Offering - TradingView — Track All Markets
FibroBiologics Closes $3M Public Offering - National Today
FibroBiologics Announces Public Offering and Warrant Agreements - TipRanks
FibroBiologics Raises $2.5 Million Net in Public Offering Priced at $1.32, Adds Warrants Upside - TradingView — Track All Markets
FibroBiologics closes $3M public offering with warrants - Investing.com
FibroBiologics (NASDAQ: FBLG) closes $3M stock and warrant offering - Stock Titan
FibroBiologics, Inc. Common Stock (FBLG) Stock Price Today & Analysis - Gotrade
FibroBiologics (NASDAQ: FBLG) sells shares and warrants; reverse split in place - Stock Titan
FibroBiologics, Inc. Announces Pricing of Public Offering for 2.27 Million Shares and Warrants - Moomoo
FBLG: Advancing Fibroblast Therapy on Multiple Fronts - Yahoo Finance
FibroBiologics manufactures first batch of CYWC628 drug product for trials - TipRanks
FibroBiologics prices $3M public offering at $1.32/share By Investing.com - Investing.com Australia
FibroBiologics completes first CYWC628 batch for clinical trials By Investing.com - Investing.com South Africa
FibroBiologics prices $3M public offering at $1.32/share - Investing.com
FibroBiologics Announces Pricing of $3 Million Public Offering - The Manila Times
After a $3M raise, FibroBiologics targets working capital needs - Stock Titan
FibroBiologics Completes Manufacturing of Diabetic Foot Ulcer Drug - National Today
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):